ClinicalTrials.gg
RecruitingNCT07949396Updated Nov 19, 2026

Application of 18F-SSTR2 Antagonist PET/CT in Neuroendocrine Tumors

An interventional study of 18F-SSTR2 Antagonist in NETs, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate the safety, distribution in normal organs, radiation dose, and diagnostic value of 18F-labeled somatostatin receptor subtype 2 (SSTR2) antagonist PET/CT imaging. Healthy volunteers will undergo imaging to assess tracer distribution and radiation exposure. Patients with pathologically confirmed grade 1 or 2 neuroendocrine tumors will undergo SSTR2 antagonist and 18F-octreotide PET/CT within 1 week to compare tumor detection and tracer uptake. Selected patients will also receive succinylated gelatin or amino acids before antagonist imaging to assess their effects on kidney and tumor uptake. Imaging findings will be compared with pathological results, SSTR2 expression, and clinical follow-up data.

02

Conditions studied

  • NETs
03

In context

Lead sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences is the lead sponsor of 396 studies on the registry; 281 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written and ability to complete imaging and follow-up.
  • Healthy volunteers: aged 18-70 years and in good health.
  • Patients: confirmed grade 1-2 neuroendocrine tumors without other history.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding; planned pregnancy in healthy volunteers.
  • Severe liver or kidney dysfunction; severe heart or lung dysfunction in healthy volunteers.
  • Relevant drug or tracer allergy in healthy volunteers.
  • Inability to lie flat for 30 minutes or complete imaging.
  • Other conditions deemed unsuitable by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    SSTR2 Antagonist PET/CT Imaging

    Participants will receive an intravenous injection of an 18F-labeled SSTR2 antagonist (0.1-0.15 mCi/kg), followed by PET/CT imaging approximately 60 minutes later. Healthy volunteers will be assessed for normal-organ tracer distribution and radiation dose. Patients with neuroendocrine tumors will also undergo 18F-octreotide PET/CT within 1 week to compare lesion detection and tracer uptake. In the renal protection substudy, patients will receive succinylated gelatin or amino acids 30 minutes before antagonist administration.

    Drug: 18F-SSTR2 Antagonist

Interventions

  • Drug18F-SSTR2 Antagonist

    18F-SSTR2 Antagonist was injected into the patients before the PET/CT scans

06

What researchers measure

Primary outcomes

  1. Lesion Detection Rates of SSTR2 Antagonist PET/CT Versus 18F-Octreotide PET/CT

    Lesion detection rates will be compared between 18F-labeled SSTR2 antagonist PET/CT and 18F-octreotide PET/CT in patients with neuroendocrine tumors. Pathology, conventional imaging, and clinical follow-up findings will serve as the reference for lesion confirmation.

    Time frame: Paired PET/CT scans within 1 week, with lesion confirmation during follow-up of up to 2 months.

07

Study locations

1 of 1 sites recruiting
  • National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, Chao Yang 100021, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Dec 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2026
First posted
Nov 19, 2026
StartActual
Sep 3, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949396
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Sep 3, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Xin Liu, M.D.
Contact
liux0077@163.com
13269997223
Xuejuan Wang, M.D.
study chair · Chinese Academy of Medical Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion